The study aimed to integrate MAC-NCs to improve pro-apoptotic effects on AGS gastric cancer cells. The synthesised MAC-NCs showed potential as a selective anti-gastric cancer agent, however, more in vivo studies are needed to confirm these findings. Gastric cancer is a significant health concern, and the search for effective treatments is ongoing. Myricetin, […]
Boron Neutron Capture Therapy for Spinal Tumors
The study aimed to evaluate the efficacy and safety of BNCT for metastatic spinal tumors. The findings suggested that BNCT could be a novel therapeutic option for managing metastatic spinal tumors. Metastatic spinal tumors pose a significant challenge in oncology, often requiring complex management strategies. While radiation therapy has advanced, improving the quality […]
Venetoclax and Hypomethylating Agents in Coexisting MM and AML
The study aimed to explore clinical features and promising treatment strategies for the rare coexistence of MM and AML. The results showed that DNMT3A clonal hematopoiesis drives the coexistence of multiple myeloma and AML. Multiple myeloma (MM) and acute myeloid leukemia (AML) are distinct hematologic malignancies arising from different cell lineages. Their coexistence […]
New Bioinformatics-Based Model for Cervical Cancer Diagnosis
The study aimed to identify cervical cancer susceptibility genes and construct a mitophagy-related diagnostic model. Researchers identified cervical cancer susceptibility genes and created a clinical model for early diagnosis and treatment. Zhang Zhang and the team aimed to use bioinformatics to systematically identify cervical cancer susceptibility genes and construct a validated mitophagy-related gene […]
HD-MT With/Without IT-MT and WBRT for Primary CNS Lymphoma
The study aimed to evaluate the efficacy and safety of HD-MT with or without IT-MT and WBRT for PCNSL. The results showed no significant difference in efficacy between HD-MT alone or with IT-MT plus radiotherapy, with manageable side effects. Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of lymphoma. […]
Spinal Chondrosarcoma Subtypes: Prognosis and Treatment Analysis
The study aimed to analyze differences in clinical, molecular, therapeutic, and prognostic factors among spinal chondrosarcoma subtypes. The results showed upregulated p53/MDM2 pathway in MCS and DCS, with radical resection crucial for spinal chondrosarcoma. Spinal chondrosarcoma is more invasive and has a worse prognosis than extremity chondrosarcoma. Prognosis and treatment vary among chondrosarcoma […]
MOST RECENT
Plasma ccfDNA & mtDNA as Biomarkers in Breast Cancer
The study aimed to evaluate ccfDNA, mtDNA, and CTCs as treatment response biomarkers and their link to EMT. The results showed plasma ccfDNA and mtDNA are potential biomarkers for monitoring chemotherapy response in breast cancer. Breast cancer is the most common cancer among women, highlighting the critical need for non-invasive blood-based biomarkers for […]
Predicting eTNBC Response With TNBC-DX Genomic Test
The study aimed to evaluate the TNBC-DX test’s ability to predict response to neoadjuvant taxane-carboplatin chemotherapy in eTNBC. The primary endpoints were to determine pCR, DDFS, and OS. Researchers found the TNBC-DX test predicts response to neoadjuvant taxane-carboplatin therapy and long-term survival in eTNBC. In this study, there was an urgent need for […]
Impact of High-Dose Vitamin D on mCRC With Chemo+Bev
The SOLARIS phase 3 trial investigated the effect of high-dose vitamin D3 on PFS in patients with mCRC. Researchers found that high-dose vitamin D3 showed no overall benefit for PFS but may help patients with mCRC. Higher 25-hydroxyvitamin D levels have been linked to improved colorectal cancer (CRC) survival. The SUNSHINE phase II […]
Efficacy of ESG401 Trop2 ADC in HER2-Negative mBC- BMs
The study aimed to investigate the efficacy of ESG401 in treating BMs in patients with HER2-negative mBC. Researchers noticed consistent responses in both brain and systemic lesions; further investigation is ongoing. The study focuses on addressing the significant unmet medical need for effective treatments targeting brain metastases (BMs) in HER2-negative metastatic breast cancer […]
Advertisement
MOST RECENT
Popular With Peers
SKB264 + KL-A167 Shows Promise in NSCLC: OptiTROP-Lung01
The study aimed to assess the efficacy and safety of combining SKB264 with KL-A167 in patients with advanced NSCLC. Researchers observed that SKB264 + KL-A167 demonstrated promising efficacy and safety; further investigation is ongoing. Sacituzumab Tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase […]
Efficacy of Fulzerasib/Cetuximab in KRAS G12C NSCLC
The phase 1 & 2 trial aimed to investigate the efficacy and safety of combining fulzerasib, with cetuximab as front-line treatment for patients with NSCLC. The primary objective was to evaluate fulzerasib with cetuximab in untreated advanced NSCLC with KRAS G12C mutation. Researchers noticed promising efficacy and safety of fulzerasib + cetuximab; further […]
TN+ SPA or RIB Therapies: Safe & Tolerated
The phase I trial aimed to assess TN’s safety and efficacy combined with SPA or RIB in advanced solid tumor patients. The results demonstrated that TN combined with SPA or RIB was well-tolerated at recommended doses, with safety profiles consistent with individual agents. Omar Saavedra Santa Gadea and the team spearheaded the study […]
VenDd Elicits Durable MRD Negativity in Myeloma
The interventional phase 2 trial aimed to compare MRD in VenDd vs. DVd RRMM. The results demonstrated that VenDd was superior MRD clearance and extended PFS in t(11;14)-positive RRMM compared to DVd. Multiple myeloma shows hematologic malignancies that involve abnormal cell proliferation in the bone marrow—the combination of venetoclax (Ven), a potent BCL-2 […]
Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC
The phase II trial aimed to evaluate the combined efficacy and safety of TUC and Tras in HER2-altered solid tumor pts. The primary endpoint was cORR. Secondary endpoints include OS, DCR, DOR, PFS, and safety. The study found that combined therapy was well-tolerated and showed promising antitumor activity in pts. Biliary tract cancer […]
Amivantamab Shows Efficacy In Pts With Advanced NSCLC
The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations. Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study. The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and […]
PSCA-Targeted CAR T Cells Show Promise in mCRPC Patients
The phase I trial aimed to evaluate the safety and efficacy of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in patients with mCRPC. CAR T cells were manufactured and infused into patients with disease progression after at least 1 androgen receptor-targeted therapy. The study found that PSCA-CAR T cells can potentially treat mCRPC, but […]
CheckMate 214 Study: Clinical Efficacy of NIVO+IPI in sRCC Patients
Phase 3 of CheckMate 214 trial was conducted to study the long-term efficacy and suitability of NIVO+IPI as a 1L treatment for patients with Untreated Advanced or Metastatic Renal Cell Carcinoma with Sarcomatoid features. 139 patients were randomized in an open-label trial to compare the NIVO+IPI combination with SUN monotherapy, where NIVO+IPI proved […]
ctDNA Testing in mCRPC Patients with HRR Gene Alterations
The phase 3 PROfound study included patients with mCRPC whose plasma samples were retrospectively sequenced using circulating tumor DNA (ctDNA) Next-Generation Sequencing (NGS) to test for BRCA/ATM alterations. The efficacy of Olaparib was consistent, irrespective of the method used to identify the BRCA/ATM alterations. The study demonstrated that ctDNA NGS might be used […]
More Oncology Studies
Head & Neck Cancer
Boron Neutron Capture Therapy for Spinal Tumors
Breast Cancer
Predicting eTNBC Response With TNBC-DX Genomic Test
Colorectal Cancer
Impact of High-Dose Vitamin D on mCRC With Chemo+Bev
Breast Cancer
Efficacy of ESG401 Trop2 ADC in HER2-Negative mBC- BMs
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
SELECT ONCOLOGY JOURNAL ARTICLES
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
1222 Antigen-specific delivery of TCR and costimulatory signals by a protein scaffold selectively activates and markedly expands naïve MART-1-specific CD8+ T cells
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
890 Nivolumab plus ipilimumab in anti-PD(L)-1 naïve and experienced HCC patients -- single institute experience in Taiwan
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …